{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:37:34Z","timestamp":1792179454469,"version":"4.4.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32372322"],"award-info":[{"award-number":["32372322"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32271230"],"award-info":[{"award-number":["32271230"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82525036"],"award-info":[{"award-number":["82525036"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2025A1515010536"],"award-info":[{"award-number":["2025A1515010536"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2024A1515011256"],"award-info":[{"award-number":["2024A1515011256"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2025A04J3677"],"award-info":[{"award-number":["2025A04J3677"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFA0806400"],"award-info":[{"award-number":["2022YFA0806400"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ymthe.2026.05.024","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T06:45:29Z","timestamp":1780382729000},"page":"4604-4620","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["An optimized engineered bacterium for tyrosinemia type 1 therapy: A multi-species preclinical study"],"prefix":"10.1016","volume":"34","author":[{"given":"Peng","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajia","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuguang","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0473-205X","authenticated-orcid":false,"given":"Peng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2026.05.024_bib1","doi-asserted-by":"crossref","DOI":"10.1002\/jimd.70089","article-title":"Overview of european practices for management of tyrosinemia type 1: towards european guidelines","volume":"48","author":"Kuypers","year":"2025","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymthe.2026.05.024_bib2","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1172\/JCI115979","article-title":"Type 1 hereditary tyrosinemia. Evidence for molecular heterogeneity and identification of a causal mutation in a french canadian patient","volume":"90","author":"Phaneuf","year":"1992","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2026.05.024_bib3","doi-asserted-by":"crossref","first-page":"2063S","DOI":"10.1093\/jn\/133.6.2063S","article-title":"Animal models reveal pathophysiologies of tyrosinemias","volume":"133","author":"Endo","year":"2003","journal-title":"J. Nutr."},{"key":"10.1016\/j.ymthe.2026.05.024_bib4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ajmg.c.30092","article-title":"The genetic tyrosinemias","volume":"142C","author":"Scott","year":"2006","journal-title":"Am. J. Med. Genet. Pt. C."},{"key":"10.1016\/j.ymthe.2026.05.024_bib5","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/hep.1840200513","article-title":"Hereditary tyrosinemia type I: a new clinical classification with difference in prognosis on dietary treatment","volume":"20","author":"Van Spronsen","year":"1994","journal-title":"Hepatology"},{"key":"10.1016\/j.ymthe.2026.05.024_bib6","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1038\/gim.2017.101","article-title":"Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations","volume":"19","author":"Chinsky","year":"2017","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymthe.2026.05.024_bib7","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S2213-8587(21)00092-9","article-title":"Long-term safety and outcomes in hereditary tyrosinaemia type 1 with nitisinone treatment: a 15-year non-interventional, multicentre study","volume":"9","author":"Spiekerkoetter","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.ymthe.2026.05.024_bib8","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10545-008-0793-1","article-title":"NTBC treatment in tyrosinaemia type I: long-term outcome in french patients","volume":"31","author":"Masurel-Paulet","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymthe.2026.05.024_bib9","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s13023-021-01879-1","article-title":"Treatment adherence in tyrosinemia type 1 patients","volume":"16","author":"Gonz\u00e1lez-Lamu\u00f1o","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymthe.2026.05.024_bib10","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S0168-8278(03)00433-1","article-title":"Extensive changes in liver gene expression induced by hereditary tyrosinemia type I are not normalized by treatment with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC)","volume":"39","author":"Luijerink","year":"2003","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ymthe.2026.05.024_bib11","doi-asserted-by":"crossref","DOI":"10.1111\/petr.14334","article-title":"Hepatocellular carcinoma requiring liver transplantation in hereditary tyrosinemia type 1 despite nitisinone therapy and \u03b11-fetoprotein normalization","volume":"26","author":"Bhushan","year":"2022","journal-title":"Pediatr. Transpl."},{"key":"10.1016\/j.ymthe.2026.05.024_bib12","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2165\/00003495-200666060-00002","article-title":"Nitisinone in the treatment of hereditary tyrosinaemia type 1","volume":"66","author":"Mckiernan","year":"2006","journal-title":"Drugs"},{"key":"10.1016\/j.ymthe.2026.05.024_bib13","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s12098-022-04128-w","article-title":"Liver transplantation for tyrosinemia type 1 in the developing world: is it really the best we can offer?","volume":"89","author":"Bolia","year":"2022","journal-title":"Indian J. Pediatr."},{"key":"10.1016\/j.ymthe.2026.05.024_bib14","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s12098-021-03826-1","article-title":"Liver transplantation: a safe and definitive alternative to lifelong nitisinone for tyrosinemia type 1","volume":"89","author":"Menon","year":"2022","journal-title":"Indian J. Pediatr."},{"key":"10.1016\/j.ymthe.2026.05.024_bib15","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41392-023-01440-5","article-title":"Applications of synthetic biology in medical and pharmaceutical fields","volume":"8","author":"Yan","year":"2023","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.ymthe.2026.05.024_bib16","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.copbio.2017.06.004","article-title":"Synthetic biology-inspired therapies for metabolic diseases","volume":"47","author":"Teixeira","year":"2017","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.05.024_bib17","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.tips.2022.02.002","article-title":"Emerging strategies for engineering Escherichia coli Nissle 1917-based therapeutics","volume":"43","author":"Lynch","year":"2022","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ymthe.2026.05.024_bib18","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.jhep.2023.10.037","article-title":"An engineered Escherichia coli Nissle strain prevents lethal liver injury in a mouse model of tyrosinemia type 1","volume":"80","author":"Gu","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ymthe.2026.05.024_bib19","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/hep.20077","article-title":"Chronic liver disease in murine hereditary tyrosinemia type 1 induces resistance to cell death","volume":"39","author":"Vogel","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.ymthe.2026.05.024_bib20","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.ymgme.2007.09.018","article-title":"Rescue from neonatal death in the murine model of hereditary tyrosinemia by glutathione monoethylester and vitamin C treatment","volume":"93","author":"Langlois","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2026.05.024_bib21","doi-asserted-by":"crossref","first-page":"4755","DOI":"10.1074\/jbc.M116.764787","article-title":"Fumarylacetoacetate hydrolase knock-out rabbit model for hereditary tyrosinemia type 1","volume":"292","author":"Li","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymthe.2026.05.024_bib22","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/S0142-9612(03)00509-X","article-title":"Large animal models of fulminant hepatic failure in artificial and bioartificial liver support research","volume":"25","author":"van de Kerkhove","year":"2004","journal-title":"Biomaterials"},{"key":"10.1016\/j.ymthe.2026.05.024_bib23","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.pharmthera.2013.10.007","article-title":"Small and large animal models in cardiac contraction research: advantages and disadvantages","volume":"141","author":"Milani-Nejad","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ymthe.2026.05.024_bib24","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1042\/bj2340593","volume":"234","author":"Fotheringham","year":"1986","journal-title":"Biochem. J."},{"key":"10.1016\/j.ymthe.2026.05.024_bib25","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.omtm.2021.04.002","article-title":"Genetically blocking HPD via CRISPR-Cas9 protects against lethal liver injury in a pig model of tyrosinemia type I","volume":"21","author":"Gu","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2026.05.024_bib26","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1055\/s-2001-19035","article-title":"The pathophysiology and treatment of hereditary tyrosinemia type 1","volume":"21","author":"Grompe","year":"2001","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.ymthe.2026.05.024_bib27","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/ng0895-453","article-title":"Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type I","volume":"10","author":"Grompe","year":"1995","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2026.05.024_bib28","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s10545-011-9394-5","article-title":"Neurocognitive outcome in patients with hypertyrosinemia type I after long-term treatment with NTBC","volume":"35","author":"Thimm","year":"2012","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymthe.2026.05.024_bib29","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1097\/MPG.0000000000002698","article-title":"Late development of hepatocellular carcinoma in tyrosinemia type 1 despite nitisinone (NTBC) treatment","volume":"71","author":"Almuqbil","year":"2020","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.ymthe.2026.05.024_bib30","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/978-3-319-55780-9_4","article-title":"Molecular pathogenesis of liver injury in hereditary tyrosinemia 1","volume":"959","author":"Tanguay","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ymthe.2026.05.024_bib31","doi-asserted-by":"crossref","first-page":"349r","DOI":"10.1126\/scitranslmed.aaf3838","article-title":"Curative ex vivo liver-directed gene therapy in a pig model of hereditary tyrosinemia type 1","volume":"8","author":"Hickey","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2026.05.024_bib32","first-page":"413","article-title":"Long-term outcomes and practical considerations in the pharmacological management of tyrosinemia type 1. Paediatr","volume":"21","author":"Van Ginkel","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.ymthe.2026.05.024_bib33","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.3390\/nu11112816","article-title":"The effect of various doses of phenylalanine supplementation on blood phenylalanine and tyrosine concentrations in tyrosinemia type 1 patients","volume":"11","author":"Van Ginkel","year":"2019","journal-title":"Nutrients"},{"key":"10.1016\/j.ymthe.2026.05.024_bib34","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau7975","article-title":"An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans","volume":"11","author":"Kurtz","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2026.05.024_bib35","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/s41467-024-45893-w","article-title":"Cas9-assisted biological containment of a genetically engineered human commensal bacterium and genetic elements","volume":"15","author":"Hayashi","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.05.024_bib36","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13036-018-0105-8","article-title":"Auxotrophy to Xeno-DNA: an exploration of combinatorial mechanisms for a high-fidelity biosafety system for synthetic biology applications","volume":"12","author":"Whitford","year":"2018","journal-title":"J. Biol. Eng."},{"key":"10.1016\/j.ymthe.2026.05.024_bib37","doi-asserted-by":"crossref","first-page":"1556S","DOI":"10.1093\/jn\/137.6.1556S","article-title":"Animal models of tyrosinemia","volume":"137","author":"Nakamura","year":"2007","journal-title":"J. Nutr."},{"key":"10.1016\/j.ymthe.2026.05.024_bib38","doi-asserted-by":"crossref","first-page":"22229","DOI":"10.1073\/pnas.1904485116","article-title":"Tissue-specific FAH deficiency alters sleep-wake patterns and results in chronic tyrosinemia in mice","volume":"116","author":"Yang","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.05.024_bib39","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1101\/gad.7.12a.2298","article-title":"Loss of fumarylacetoacetate hydrolase is responsible for the neonatal hepatic dysfunction phenotype of lethal albino mice","volume":"7","author":"Grompe","year":"1993","journal-title":"Genes Dev."},{"key":"10.1016\/j.ymthe.2026.05.024_bib40","first-page":"2285","article-title":"Rescue of mice homozygous for lethal albino deletions: implications for an animal model for the human liver disease tyrosinemia type 1. Genes","volume":"7","author":"Kelsey","year":"1993","journal-title":"Dev."},{"key":"10.1016\/j.ymthe.2026.05.024_bib41","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12943-025-02492-7","article-title":"Metabolic characteristics in hepatocellular carcinoma: amino acid metabolic reprogramming","volume":"25","author":"Zhou","year":"2026","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ymthe.2026.05.024_bib42","doi-asserted-by":"crossref","first-page":"4641","DOI":"10.1073\/pnas.74.10.4641","article-title":"On the enzymic defects in hereditary tyrosinemia","volume":"74","author":"Lindblad","year":"1977","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.05.024_bib43","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1136\/jmedgenet-2016-104289","article-title":"Hypersuccinylacetonaemia and normal liver function in maleylacetoacetate isomerase deficiency","volume":"54","author":"Yang","year":"2017","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymthe.2026.05.024_bib44","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3138\/canlivj-2023-0018","article-title":"Decoding hepatorenal tyrosinemia type 1: unraveling the impact of early detection, NTBC, and the role of liver transplantation","volume":"7","author":"Kehar","year":"2024","journal-title":"Can. Liver J."},{"key":"10.1016\/j.ymthe.2026.05.024_bib45","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1002\/pbc.25094","article-title":"HCC prevalence and histopathological findings in liver explants of patients with hereditary tyrosinemia type 1","volume":"61","author":"Seda Neto","year":"2014","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.ymthe.2026.05.024_bib46","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/978-3-319-55780-9_9","article-title":"Liver cancer in tyrosinemia type 1","volume":"959","author":"Van Ginkel","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ymthe.2026.05.024_bib47","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1006\/mgme.2001.3266","article-title":"Long-term therapy with NTBC and tyrosine-restricted diet in a murine model of hereditary tyrosinemia type I","volume":"75","author":"Al-Dhalimy","year":"2002","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2026.05.024_bib48","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ymgme.2022.07.001","article-title":"Biochemical and behavioural profile of NTBC treated tyrosinemie type 1 mice","volume":"137","author":"Van Ginkel","year":"2022","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2026.05.024_bib49","doi-asserted-by":"crossref","first-page":"693","DOI":"10.3390\/genes14030693","article-title":"Hereditary tyrosinemia type 1 mice under continuous nitisinone treatment display remnants of an uncorrected liver disease phenotype","volume":"14","author":"Neuckermans","year":"2023","journal-title":"Genes"},{"key":"10.1016\/j.ymthe.2026.05.024_bib50","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41575-025-01041-3","article-title":"A consensus statement on establishing causality, therapeutic applications and the use of preclinical models in microbiome research","volume":"22","author":"Metwaly","year":"2025","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ymthe.2026.05.024_bib51","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.ymthe.2020.11.023","article-title":"CRISPR\/Cas9-mediated gene correction in newborn rabbits with hereditary tyrosinemia type I","volume":"29","author":"Li","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.05.024_bib52","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/s41434-023-00390-5","article-title":"Successes and challenges in clinical gene therapy","volume":"30","author":"Kohn","year":"2023","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2026.05.024_bib53","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41587-020-0565-5","article-title":"The delivery challenge: fulfilling the promise of therapeutic genome editing","volume":"38","author":"Van Haasteren","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.05.024_bib54","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/1535676019899502","article-title":"Viral vector systems for gene therapy: a comprehensive literature review of progress and biosafety challenges","volume":"25","author":"Ghosh","year":"2020","journal-title":"Appl. Biosaf."},{"key":"10.1016\/j.ymthe.2026.05.024_bib55","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1038\/s41587-022-01244-y","article-title":"A programmable encapsulation system improves delivery of therapeutic bacteria in mice","volume":"40","author":"Harimoto","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.05.024_bib56","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.chom.2022.12.004","article-title":"Biomarker-responsive engineered probiotic diagnoses, records, and ameliorates inflammatory bowel disease in mice","volume":"31","author":"Zou","year":"2023","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.ymthe.2026.05.024_bib57","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.chom.2024.01.005","article-title":"The live biotherapeutic SYNB1353 decreases plasma methionine via directed degradation in animal models and healthy volunteers","volume":"32","author":"Perreault","year":"2024","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.ymthe.2026.05.024_bib58","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2024.2397874","article-title":"Benefits and concerns of probiotics: an overview of the potential genotoxicity of the colibactin-producing Escherichia coli Nissle 1917 strain","volume":"16","author":"Falzone","year":"2024","journal-title":"Gut Microbes"},{"key":"10.1016\/j.ymthe.2026.05.024_bib59","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/s41591-019-0544-x","article-title":"A novel pathway for microbial metabolism of levodopa","volume":"25","author":"Jameson","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.05.024_bib60","doi-asserted-by":"crossref","first-page":"6215","DOI":"10.1038\/s41467-021-26524-0","article-title":"Improvement of a synthetic live bacterial therapeutic for phenylketonuria with biosensor-enabled enzyme engineering","volume":"12","author":"Adolfsen","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.05.024_bib61","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1038\/s42255-023-00897-6","article-title":"Efficacy and safety of a synthetic biotic for treatment of phenylketonuria: a phase 2 clinical trial","volume":"5","author":"Vockley","year":"2023","journal-title":"Nat. Metab."},{"key":"10.1016\/j.ymthe.2026.05.024_bib62","doi-asserted-by":"crossref","first-page":"6125","DOI":"10.1007\/s00253-022-12145-0","article-title":"Developing a dynamic equilibrium system in Escherichia coli to improve the production of recombinant proteins","volume":"106","author":"Zhang","year":"2022","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.05.024_bib63","doi-asserted-by":"crossref","DOI":"10.15252\/msb.202110539","article-title":"An engineered bacterial therapeutic lowers urinary oxalate in preclinical models and in silico simulations of enteric hyperoxaluria","volume":"18","author":"Lubkowicz","year":"2022","journal-title":"Mol. Syst. Biol."},{"key":"10.1016\/j.ymthe.2026.05.024_bib64","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41586-022-05299-4","article-title":"Gut bacteria alleviate smoking-related NASH by degrading gut nicotine","volume":"610","author":"Chen","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.05.024_bib65","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.jhep.2015.10.020","article-title":"Cerium oxide nanoparticles reduce steatosis, portal hypertension and display anti-inflammatory properties in rats with liver fibrosis","volume":"64","author":"Or\u00f3","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ymthe.2026.05.024_bib66","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.chom.2023.11.006","article-title":"Oral magnesium prevents acetaminophen-induced acute liver injury by modulating microbial metabolism","volume":"32","author":"Li","year":"2024","journal-title":"Cell Host Microbe"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626004685?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626004685?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T20:48:15Z","timestamp":1785962895000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001626004685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":66,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1525001626004685"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.05.024","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An optimized engineered bacterium for tyrosinemia type 1 therapy: A multi-species preclinical study","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.05.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}